Concurrent expressions of metallothionein, glutathione S-transferase-π, and P-glycoprotein in colorectal cancers

Sutoh, Ichiro; Kohno, Hitoshi; Nakashima, Yuuichi; Hishikawa, Yoshitaka; Tabara, Hideki; Tachibana, Mitsuo; Kubota, Hirofumi; Nagasue, Naofumi

doi:10.1007/bf02236987

Cited by 27 publications

(28 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, to date, only limited information is available regarding the role of MT in colorectal carcinoma patients [13, 14, 15]. Öfner et al [13]reported that only 24% of the patients with Dukes D colon carcinoma were positive for MT and almost a similar percentage (21%) of patients were found to be positive in our patients.…”

Section: Discussionmentioning

confidence: 83%

“…It was considered as an important mechanism during tumor progression and appears to be predominantly correlated with more advanced, highly malignant tumors [11, 12]. However, to date only limited information is available regarding the role of MT in the pathogenesis of colorectal cancer and drug resistance in colorectal cancer patients [13, 14, 15]. In the present study, we have investigated MT expression in primary colorectal tumors and their corresponding liver metastatic lesion by immunohistochemistry, and have addressed whether MT expression at these two sites could affect the prognosis and drug resistance potential with regard to cisplatin.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of Metallothionein in Colorectal Cancers and Synchronous Liver Metastases

Hishikawa¹,

Kohno²,

Ueda³

et al. 2001

Oncology

Self Cite

View full text Add to dashboard Cite

The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis. Immunohistochemical staining for MT was performed on the specimens of adenocarcinoma of the colon and rectum and its liver metastases in 34 patients treated with curative surgery, respectively. Expression of MT was compared with clinicopathological variables and patient survival. In patients with primary colorectal cancer, positive expression was found in 7 of 34 (20.6%) patients, but MT was not detected in any of the cases of liver metastases (0%; p = 0.0111). In the primary tumor, positive MT expression was significantly associated with a higher degree of lymph node involvement (mean ± SD: 48.4 ± 33.8 vs. 18.6 ± 24.4% in MT-positive and MT-negative tumors, respectively; p = 0.0122). The survival rate in the patients with MT-negative tumors was significantly better than that in those with MT-positive tumors as primary sites (p = 0.0198). MT expression in colorectal cancer may be a potential marker affecting lymph node metastases and may be a predictor of a poor prognosis, particularly in patients with synchronous liver metastases.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Expression of Metallothionein in Colorectal Cancers and Synchronous Liver Metastases

Hishikawa¹,

Kohno²,

Ueda³

et al. 2001

Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In CRC, several reports have studied MT1 + 2 immunohistochemical expression, showing that MTs are heavily down-regulated in this tumor type. However, its association with patient prognosis is far from clear, with most reports showing a lack of correlation between MT and OS and DFS [17][18][19][20]. Ofner et al [21], however, report a statistically significant association of these variables with lower MT levels, whereas another study associated higher MT expression with worse prognosis, although the number of cases was low [22].…”

Section: Discussionmentioning

confidence: 93%

Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival

Arriaga

Levy

Bravo³

et al. 2012

Human Pathology

View full text Add to dashboard Cite

“…In most of the cases high level of the protein was linked to poor prognosis. Several authors showed an evident relationship between intensity of MT expression and clinical advancement of the tumours, frequency of metastasis development, as well as shortening of survival rate and disease free survival [17,28,[31][32][33][34]. In some tumours also a significant correlation between high levels of MT and unfavourable results of treatment was observed [30,35,36].…”

Section: Discussionmentioning

confidence: 99%

Correlation between metallothionein (MT) expression and selected prognostic factors in ductal breast cancers.

Gomułkiewicz

Podhorska-Okołów²,

Szulc³

et al. 2010

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:Our study aimed at examining significance of metallothionein (MT) expression in ductal breast cancers by determination of a relationship between expression of MT protein (MT-1/2) and selected prognostic factors, including grade of histological differentiation (G), expression of Ki-67 proliferative antigen, expression of estrogen receptors (ER) and progesterone receptors (PgR) and expression of HER-2 receptor. Material for the studies involved 54 samples of invasive ductal breast cancer, manifesting malignancy grades of G1-G3. In paraffin sections of examined tumours immunohistochemical reactions were performed using specific antibodies directed to MT, Ki-67, ER, PgR or HER-2. Intensity of MT-specific immunohistochemical reactions was measured using the semiquantitative IRS scale of Remmele. Intensity of colour reactions targeted at Ki-67, ER, PgR was evaluated scoring proportions of positive cells, while HER-2-specific reactions were evaluated in the scale of 0-3 points. The lowest level of MT expression was detected in breast cancer cases of G1 malignancy grade (G1 vs G3 p=0.020). A positive correlation between MT and Ki-67 antigen expression (r=0.32, p=0.019) was disclosed. Moreover, MT expression exhibited negative correlations with expression of ER (r=-0.35, p=0.008) and PgR (r=-0.27, p=0.046). No relationships could be detected between expression of MT and expression of HER-2 (r=0.12, p=0.37). The obtained results suggest that MT expression might be helpful in prognostic evaluation of ductal breast cancers. Abbreviations: MT -metallothionein; Ki-67 -proliferative antigen; ER -estrogen receptor; PgR -progesterone receptor; HER-2 -human epidermal growth factor receptor 2; G -grade of histological differentiation; IRS -immuno-reactive score

show abstract

Concurrent expressions of metallothionein, glutathione S-transferase-π, and P-glycoprotein in colorectal cancers

Abstract: The patients with concurrent expression of drug-resistant proteins in their cancers had worse prognoses. Examining drug-resistant proteins in colorectal cancers may be useful in selecting adjuvant chemotherapy and in predicting prognosis more accurately.

Cited by 27 publications

References 42 publications

Expression of Metallothionein in Colorectal Cancers and Synchronous Liver Metastases

Expression of Metallothionein in Colorectal Cancers and Synchronous Liver Metastases

Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival

Correlation between metallothionein (MT) expression and selected prognostic factors in ductal breast cancers.

Contact Info

Product

Resources

About